Skip to main content

Table 1 Results of interrupted time series analysis of 12 innovative anticancer drugs

From: Impact of medical insurance access negotiation on the utilization of innovative anticancer drugs in China: an interrupted time series analysis

Drug

Drug expenditures (US$)

 

DDDs

Intercept β0

Baseline trend

β1

Level change after MIAN β2

Trend change after MIAN β3

 

Intercept β0

Baseline trend

β1

Level change after MIAN β2

Trend change after MIAN β3

Afatinib

8,500

-115.74

323,383**

134,647***

 

172.98

-1.93

11,615**

5,044***

Axitinib

86,661

-523.95

291,255***

73,488***

 

345.76

12.68

5,653***

1,201***

Octreotide

755,307

7,284

-70,982

36,415***

 

17,411

336.78

5,525

1,301**

Osimertinib

291,844

3,160

4,514,591***

1,112,752***

 

1,021

30.94

63,063***

15,180***

Crizotinib

375,945

-4,083

1,625,733***

403,016***

 

1,228

28.43

23,887***

5,347***

Nilotinib

2,029,676

-11,501

-1,086,056***

209,580***

 

10,766

6.73

2,790

3,486***

Pegaspargase

1,034,835

14,284

-113,896

-36.85

 

7,454

121.10

1,697

55.08

Pazopanib

7,859

10,096

250,417**

58,425***

 

-28.50

42.69

3,619***

701.62***

Regorafenib

18,490

1,094

1,204,753***

168,215***

 

76.36

7.10

10,590***

1,497***

Sunitinib

804,672

-6,059

-79,592

92,918***

 

3,180

-0.83

4,148***

952.59***

Cetuximab

2,653,678

16,055

321,573

387,434***

 

3,642

87.10

9,586***

1,792***

Ibrutinib

18,644

4,075

1,530,797***

207,407***

 

88.64

71.75

56,800***

7,718***

Overall

8,155,256

28,948

8,734,414**

2,889,078***

 

37,480.70

739.50

158,192.50***

38,715.30***

  1. Note: ***p < 0.01, **p < 0.05
Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us